TradeUP Acquisition Corp - UPTDW STOCK NEWS

Welcome to our dedicated page for TradeUP Acquisition news (Ticker: UPTDW), a resource for investors and traders seeking the latest updates and insights on TradeUP Acquisition stock.

Estrella Immunopharma, Inc., formerly known as TradeUP Acquisition Corp., is now operating under the name Estrella Immunopharma, Inc. after merging with Estrella Biopharma, Inc. It is a preclinical-stage biopharmaceutical company focusing on developing T-cell therapies for blood cancers and solid tumors. Led by Dr. Cheng Liu, the company's mission is to leverage the human immune system to revolutionize cancer treatment. Their lead product candidate, EB103, targets CD19, a protein present in most B-cell leukemias and lymphomas. Additionally, Estrella is collaborating with Imugene Limited to combine EB103 with an oncolytic virus to treat solid tumors.

09/29/2023 10:34 AM

News

TradeUP Acquisition Corp. and Estrella Biopharma, Inc. Announce Completion of Business Combination

Rhea-AI Summary

Estrella Immunopharma, Inc. successfully closes business combination with Estrella Biopharma, Inc. and will begin trading on NASDAQ under the ticker symbols 'ESLA' and 'ESLAW' starting October 2, 2023. The combined entity has approximately $23.11 million in available cash. Estrella's anti-CD19 ARTEMIS T-cell therapy shows potential in improving patient outcomes for blood cancer treatments.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is Estrella Immunopharma, Inc. focused on?

Estrella Immunopharma, Inc. is focusing on developing T-cell therapies for blood cancers and solid tumors.

Who is leading Estrella Immunopharma, Inc.?

Dr. Cheng Liu is leading Estrella Immunopharma, Inc. as the Founder and CEO.

What is Estrella's lead product candidate and its target?

Estrella's lead product candidate is EB103, which targets CD19, a protein expressed in most B-cell leukemias and lymphomas.

What is Estrella's collaboration with Imugene Limited about?

Estrella is collaborating with Imugene Limited to combine EB103 with an oncolytic virus to treat solid tumors.

What is the main goal of Estrella Immunopharma, Inc.?

The main goal of Estrella Immunopharma, Inc. is to harness the human immune system to transform the lives of cancer patients.

Who did Estrella merge with?

Estrella merged with Estrella Biopharma, Inc., resulting in the formation of Estrella Immunopharma, Inc.

When will Estrella's stock start trading on NASDAQ?

Estrella's stock will start trading on NASDAQ under the ticker symbols "ESLA" and "ESLAW" beginning October 2, 2023.

What financing activities took place before the business combination?

Before the business combination, Estrella closed Series A preferred stock financings and short-term debt financing, while UPTD closed a private placement of UPTD common stock.

What is the total available cash of the combined entity after the business combination?

The combined entity has approximately $23.11 million available cash after accounting for UPTD stockholder redemption and before payment of transaction and offering expenses.

What is the significance of Estrella's anti-CD19 ARTEMIS T-cell therapy?

Estrella's anti-CD19 ARTEMIS T-cell therapy has the potential to enhance patient outcomes and reduce the risk of Cytokine Release Syndrome (CRS) in blood cancer treatments.

TradeUP Acquisition Corp

Nasdaq:UPTDW

UPTDW Rankings

N/A Ranked by Market Cap

N/A Ranked by Dividends